Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin + Nirogacestat + Pomalidomide in Relapsed/Refractory Multiple Myeloma
NCT05556798Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2022
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of belantamab mafodotin in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Dose-Limiting Toxicities at 6 weeks. Started Oct 2022; status: active, not recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05556798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05556798.